Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2

被引：1
|
作者：
Stringer, Bradley
Chouitar, Johara
Cerbone, Jacqualine
Fortin, Sarah
Ainbinder, Alina
Kysilovsky, Cassie
Scott, Brittany
Banerjee, Antara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB063
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action
    Schade, Babette
    Brack, Simon
    Attinger-Toller, Isabella
    Klupsch, Kristina
    Woods, Richard
    Hachemi, Helen
    von der Bey, Ulrike
    Kooenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    CANCER RESEARCH, 2014, 74 (19)
  • [2] VRN101099, Brain Permeable HER2 Kinase Inhibitor, Shows the Anti-tumor Activity in Preclinical Models of HER2-positive Cancers
    Ko, Yikyung
    Yoo, Jihye
    Jung, Hong-Ryul
    Lim, Hyerim
    Lee, YeongDeok
    Kim, Se Hyuk
    Shin, Dong Guk
    Cho, Serin
    Heo, Myung Hoe
    Kim, Haelee
    Cho, Ha Yeon
    Han, Ah Reum
    Ko, Eunhwa
    Choi, Hwan Geun
    Kim, Deakwon
    Kim, Sunghwan
    CANCER RESEARCH, 2023, 83 (05)
  • [3] VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models
    Jung, Hong-ryul
    Kim, Sunghwan
    Yoo, Jihye
    Park, Chan Mi
    Lee, Somi
    Lee, Hyoju
    Lee, Youngyi
    Park, Jinhee
    Seo, Kyungah
    Seo, Dong-Hyuk
    Ko, Eunhwa
    Son, Jung Beom
    Kim, Deakwon
    Choi, Hwan Geun
    Kim, Nam Doo
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Anti-tumor activity of selinexor is enhanced by palbociclib in preclinical models of HER2+breast cancer
    Chang, Hua
    Friedlander, Sharon
    Kashyap, Trinayan
    Klebanov, Boris
    Argueta, Christian
    Gonzalez, Oscar A.
    Baloglu, Erkan
    Landesman, Yosef
    Shacham, Sharon
    Lee, Margaret
    Senapedis, William
    CANCER RESEARCH, 2017, 77
  • [5] A novel bispecific antibody-drug conjugate targeting HER2 and Trop-2 displays potent antitumor activity in a variety of tumor models with promising preclinical characteristics
    Zhong, Haihong
    Xiong, Yan
    Huang, Han
    Pan, Yuming
    Wang, Na
    Sun, Bin
    Liu, Shen
    Yuan, Wei
    Liu, Dingguo
    Fang, Jan
    Bao, Haifeng
    CANCER RESEARCH, 2024, 84 (06)
  • [6] GBR1302-BEAT® bispecific antibody targeting CD3 and HER2 demonstrates a higher anti-tumor potential than current HER2-targeting therapies
    Back, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
    Estrada-Bernal, A.
    Le, A. T.
    Doak, A. E.
    Doebele, R. C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E45 - E45
  • [8] A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
    Rau, Alexander
    Kocher, Katharina
    Rommel, Mirjam
    Kuehl, Lennart
    Albrecht, Maximilian
    Gotthard, Hannes
    Aschmoneit, Nadine
    Noll, Bettina
    Olayioye, Monilola A.
    Kontermann, Roland E.
    Seifert, Oliver
    MABS, 2021, 13 (01)
  • [9] Preclinical assessment of anti-tumor activity and immune response in syngeneic tumor models
    Franklin, M.
    Thayer, M.
    Draper, D.
    Saims, D.
    Wise, S.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S97 - S97
  • [10] HER2 TKIs enhance the anti-tumor activity of HER2-targeting CAR-T and CAR-NK cells against NSCLC
    Yang, Yan
    Nilsson, Monique B.
    Poteete, Alissa
    He, Junqin
    Huang, Qian
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (06)
12345